Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diacerein + glucosamine
- Development stage
- Unknown
- Lead developer
- Pharma Drugs & Chemicals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cartia D is a combination pharmaceutical product typically used for the management of osteoarthritis and other degenerative joint conditions. It contains two active ingredients: diacerein and glucosamine. Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) that works by inhibiting the production and activity of interleukin-1 beta (IL-1β), a pro-inflammatory cytokine that plays a central role in cartilage degradation and joint inflammation. Glucosamine is an amino sugar that serves as a structural building block for glycosaminoglycans and proteoglycans, which are essential components of the cartilage matrix. The combination is designed to provide both anti-inflammatory relief and structural support to the joints, potentially slowing the progression of joint degeneration and improving patient mobility. It is marketed in India by companies such as Pharma Drugs & Chemicals under a PCD franchise and third-party manufacturing model.
- Brand names
- Cartia DCartiaid-D
- Other names
- Cartia DCartiaid-D
02
Targets
CASP1 (Caspase-1)MMP9 (Matrix metalloproteinase-9)TGFB1 (Transforming growth factor Beta-1 proprotein)Interleukin-1 beta signaling axisMMP3 (Matrix metalloproteinase-3)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on diacerein + glucosamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diacerein + glucosamine.